AstraZeneca and Targacept announce first top-line Phase III results for TC-5214 as an adjunct treatment in patients with major depressive disorder
8 November 2011 | By AstraZeneca
Top-line results announced...
List view / Grid view
News
12-week on-treatment results from large Phase IIb study (COMMAND-1) of Bristol-Myers Squibb’s NS5A inhibitor daclatasvir support anti-HCV activity and safety profile observed in earlier studies
8 November 2011 | By Bristol-Myers Squibb Company
Study evaluated daclatasvir as add-on to peginterferon alfa/ribavirin (alfa/RBV)...
Novartis Phase III study shows ACZ885 helped substantially reduce steroid use in 45% of patients with serious form of childhood arthritis
7 November 2011 | By Novartis
New pivotal Phase III data announced...
GSK presents phase III results for eltrombopag in hepatitis C virus related thrombocytopenia
7 November 2011 | By GSK
Full results from ENABLE 1 and initial data from ENABLE 2 presented...
Pfizer to present clinical data from its hematology portfolio
7 November 2011 | By Pfizer
Investigator research on several pfizer compounds to be presented...
FDA approves ERBITUX® (cetuximab) for first-line Recurrent Locoregional or Metastatic Head and Neck Cancer in Combination with Platinum-based Chemotherapy with 5-Fluorouracil
7 November 2011 | By Bristol-Myers Squibb Company
ERBITUX now approved for five indications across two tumor types...
Abbott presents HUMIRA® (adalimumab) Phase 3 study results
7 November 2011 | By Abbott
In ABILITY-1 Study Presented at ACR, More than Twice as Many Patients Treated with HUMIRA Met Primary Endpoint Compared to Placebo...
Interim data for Merck’s VICTRELIS™ (boceprevir) in prior null responder patients with Chronic Hepatitis C genotype 1 to be presented
5 November 2011 | By Merck
PROVIDE study results...
Treatment with Enbrel® (etanercept) shows significant and sustained clinical benefits in Rheumatoid Arthritis (RA) patients with moderately active disease
5 November 2011 | By Pfizer
PRESERVE trial results...
Positive five-year data showing effect of Viread(R) on liver fibrosis and cirrhosis caused by Chronic Hepatitis B
5 November 2011 | By
New long-term data show no development of resistance...
Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial
5 November 2011 | By Amgen
Positive data of the pivotal Phase 3 fracture trial...
Abbott announces new long-term data evaluating sse of HUMIRA® (Adalimumab) for patients with long-standing moderate to severe Rheumatoid Arthritis and for patients with early moderate to severe RA
5 November 2011 | By Abbott
PREMIER Eight-Year and DE019 10-Year Data Presented at ACR 2011...
GlaxoSmithKline reaches agreement in principle to resolve multiple investigations with US Government
3 November 2011 | By GlaxoSmithKline
$3 billion settlement covered by existing legal provisions...
ASLAN Pharmaceuticals and Bristol-Myers Squibb enter innovative partnership
3 November 2011 | By Bristol-Myers Squibb Company
Innovative strategic partnership to license and develop investigational oncology compound...
Abbott to present new data for key vascular products at TCT 2011
3 November 2011 | By Abbott
Abbott announced the company's schedule of key data presentations at the 23rd annual TCT scientific symposium...
